Innomedica is strengthening its presence in Central Europe. The new office in Zürich area will provide Innomedica’s clients with access to one of the strongest financial markets for life sciences in Europe and the most influential pharmaceutical and medical technology areas globally.

”The Swiss office will bring significant added value to Innomedica’s clients,” explains Dr. Kalevi Kurkijärvi, Chairman of the Board and majority owner of Innomedica Ltd. “The central location in the leading life science cluster in Europe and local networks will increase the efficiency of our licensing and strategy consulting services to our North American, Japanese and Northern European clients.”

”Our aim is also to increase our client base within Swiss and Central European life sciences companies, which will bring great synergy benefits for both our current and future clients. Especially in Switzerland there is a large number of innovative biotech companies and a well-functioning life sciences financial market. Local companies are well placed to bring their products to market or drug candidates to a value inflection point in clinical development. There is a steady need for Innomedica’s expertise in Japan licensing among others,” concludes Tanja Dowe, Managing Partner of Innomedica Ltd.

Innomedica is Europe’s leading boutique consulting firm specialized in life science and biotechnology markets. The company provides licensing and strategy consulting services in pharmaceutical, biotechnology and medical technology areas. Innomedica’s leverage to Japan market differentiates the company from its competitors.

Innomedica Ltd is a privately owned company established in 1997. To date Innomedica has provided services to more than 250 life sciences and biotechnology companies globally. Presently Innomedica has offices in Helsinki, Tokyo and London.

Further information:

Dr. Kalevi Kurkijärvi, Chairman of the Board, tel: +358-500-825 123 Ms. Tanja Dowe, Managing Partner, tel: +358-400-636 107, +41 -78-405 4956